NEW YORK — A real-world study showed that Vabysmo helps improve visual acuity and anatomic parameters in patients with neovascular age-related macular degeneration.
Carl J. Danzig, MD, FASRS, presented results from the TRUCKEE study at the American Society of Retina Specialists annual meeting. The study explored the efficacy and safety of Vabysmo (faricimab, Genentech) in real-world patients with neovascular AMD.
“Our target population was treatment-naive but mostly hard-to-treat patients, the ones who are high need,” he said.
The study comprised 421 eyes of 377 patients for a